We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Evelo Biosciences Inc (EVLO) COM USD0.001

Sell:$2.15 Buy:$2.16 Change: $0.04 (1.90%)
NASDAQ:0.90%
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$2.15
Buy:$2.16
Change: $0.04 (1.90%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$2.15
Buy:$2.16
Change: $0.04 (1.90%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing an orally delivered investigational medicines that acts on cells in the small intestine to produce therapeutic effects throughout the body. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are orally delivered pharmaceutical preparations of single strains of microbes or microbial extracellular vesicles. Its product candidate, EDP1815, is being developed for the treatment of inflammatory diseases. Its other product candidates in development include EDP1867 and EDP2939 for the treatment of inflammatory disease. It has developed an integrated platform namely, SINTAX Medicine Platform, which is designed to identify individual strains of microbes capable of modulating the immune system by acting on SINTAX when administered at pharmacologically active doses and appropriately formulated.

Contact details

Address:
620 MEMORIAL DRIVE SUITE 500
CAMBRIDGE
02139
United States
Telephone:
+1 (781) 4792974
Website:
https://evelobio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EVLO
ISIN:
US2997341035
Market cap:
$231.97 million
Shares in issue:
107.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Balkrishan Gill
    President, Chief Executive Officer, Interim Chief Financial Officer, Director
  • Mark Bodmer
    Chief Scientific Officer, President of Research and Development
  • Daniel Char
    General Counsel, Secretary
  • Duncan McHale
    Chief Medical Officer
  • Mark Plinio
    Chief Commercial Officer
  • Jonathan Zung
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.